What Is The Forecast Valuation Of The Global Juvenile Macular Degeneration Treatment Market Projected To Reach $1.87 Billion By 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Juvenile Macular Degeneration Treatment Market Today And What Is Its Future Size?
In recent times, there has been remarkable growth in the market size of treatments for juvenile macular degeneration. The value of this market is predicted to expand from $1.28 billion in 2024 to $1.39 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. The growth recorded in the historical period can be linked to the surge in genetic eye disorders, escalating investment in research related to ophthalmology, heightened emphasis on child eye care, a rising trend in vision impairment among young individuals, and the growing adoption of artificial intelligence in the diagnostic methods for eye care.
Over the coming years, the adolescent macular degeneration treatment market is projected to experience robust growth. The market is anticipated to reach $1.87 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.8%. The growth within the forecasted time frame can be credited to an increase in the elderly population, the proliferation of ophthalmic biotechnology start-ups, a heightened focus on target-specific drug delivery systems, a rise in clinical trials, and uplifted investment in gene therapy. The forecast period will likely see significant trends including progress in genetic testing, the evolution of gene therapies, advancements in stem cell research, regulatory encouragement for innovating treatments, and a stronger emphasis on personalized medicine methods.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23433&type=smp
Which Key Factors Are Fueling Growth In The Juvenile Macular Degeneration Treatment Market?
The escalating presence of disorders affecting the retina is anticipated to propel the growth of the juvenile macular degeneration treatment market. Retinal disorders pertain to several conditions that negatively impact the retina – the light-sensitive layer at the back of the eye, often causing visual damage or complete loss of sight. They are commonly a result of increasing cases of diabetes that lead to afflictions such as diabetic retinopathy, which gradually damages the retina. Treatments for juvenile macular degeneration significantly aid in managing retinal disorders by conserving vision via early intervention, especially vital for younger patients. For instance, in November 2024, a report from Retina Australia, a non-profit Australian organization, disclosed that roughly 19,000 individuals, approximately 1 in 1,380 people, are presumed to be afflicted with an inherited retinal disease (IRD) in Australia. Moreover, as per the National Eye Institute, a health institute based in the USA, there’s an expectation of an increase in Americans suffering from advanced age-related macular degeneration (AMD) from the current 2.1 million to 3.7 million by 2030. Consequently, the escalating cases of retinal disorders are propelling the expansion of the juvenile macular degeneration treatment market.
How Is The Juvenile Macular Degeneration Treatment Market Segmented Across Key Categories?
The juvenile macular degeneration treatmentmarket covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration; Dry Age-Related Macular Degeneration
2) By Treatment: Devices; Drugs; Surgery
3) By Application: Vision Preservation; Disease Management; Symptom Relief; Preventive Care; Clinical Trials
4) By Sales Channel: Hospitals; Ambulatory Surgical Centres; Other Sales Channel
Subsegments:
1) By Wet Age-Related Macular Degeneration: Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapy; Photodynamic Therapy (PDT); Laser Therapy
2) By Dry Age-Related Macular Degeneration: Nutritional Supplements; Gene Therapy; Stem Cell Therapy
What Future-Focused Trends Are Anticipated In The Juvenile Macular Degeneration Treatment Market?
Leading firms in the juvenile macular degeneration treatment industry are working on creating novel solutions, including dual adeno-associated viral (AAV) vectors, to boost the delivery of gene therapy and enhance treatment efficiency for juvenile macular degeneration sufferers. Dual adeno-associated viral (AAV) vectors use two AAV vectors to transport large therapeutic genes which surpass the packaging ability of a single AAV. For example, SpliceBio, a biotech company from Spain, revealed in March 2025 that the initial patient had received a dose in their Phase 1/2 ASTRA study for SB-007, a dual AAV vector gene therapy formulated to re-established full ABCA4 protein expression. The intention of this therapy is to offer a possible solution for juvenile macular degeneration (also known as Stargardt disease) – a genetic retinal issue with no approved treatments, by catering to all patients irrespective of their mutations. This achievement signifies a considerable stride towards creation of efficient gene therapies for uncommon retinal diseases.
Who Are The Leading Companies Driving The Juvenile Macular Degeneration Treatment Market?
Major companies operating in the juvenile macular degeneration treatment market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AbbVie Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Samsung Bioepis Co. Ltd., Spark Therapeutics Inc., Polpharma Biologics S.A., OrCam Technologies Ltd., Alkeus Pharmaceuticals Inc., Bioeq AG, NuEyes Technologies Inc., Coherus BioSciences Inc., eSight Eyewear Inc., MeiraGTx Holdings plc, Kubota Pharmaceutical Holdings Co. Ltd.
Access The Complete Report Here:
Which Region Dominates The Juvenile Macular Degeneration Treatment Market Today?
North America was the largest region in the juvenile macular degeneration treatment market in 2024. The regions covered in the juvenile macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=23433&type=smp
Browse Through More Reports Similar to the Global Juvenile Macular Degeneration Treatment Market 2025, By The Business Research Company
Indexed And Whole Juvenile Life Insurance Global Market Report 2025
Macular Degeneration Treatment Global Market Report 2025
Age Related Macular Degeneration Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
